Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Clinical trial NCT06698250 · RECRUITING

Trial details

NCT number: NCT06698250
Sponsor: Anwaar Saeed
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-12-18
Primary completion: 2026-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.